Antidepressant compounds: A critical review

Depression: From Psychopathology to Pharmacotherapy

Volumn 27, Issue , 2010, Pages 1-19

  Tang, Siu Wa ^a   Helmeste, D M ^a   Leonard, Brian E ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84886475022     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000319425     Document Type: Chapter

References (95)

1. Miller EJ, Chung H: A literature review of studies of depression and treatment outcomes among US College students since 1990. Psychiatr Serv 2009;60:1257-1260.
2. Song Y, Huang Y, Liu D, Kwan JS, Zhang F, Sham PC, Tang SW: Depression in college: depressive symptoms and personality factors in Beijing and Hong Kong college freshmen. Compr Psychiatry 2008;49:496-502.
3. Wong JG, Cheung EP, Chan KK, Ma KK, Tang SW: Web-based survey of depression, anxiety and stress in first-year tertiary education students in Hong Kong. Aust NZ J Psychiatry 2006;40:777-782.
4. Whooley MA, de Jonge P, Vittinghoff E, Otte C, Moos R, Carney RM, Ali S, Dowray S, Na B, Feldman MD, Schiller NB, Browner WS: Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA 2008;300:2379-2388.
5. Cohen BE, Panguluri P, Na B, Whooley MA: Psychological risk factors and the metabolic syndrome in patients with coronary heart disease: findings from the Heart and Soul Study. Psychiatry Res 2010;175:133-137.
6. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006;163:1905-1917.
7. Nierenberg AA, Husain MM, Trivedi MH, Fava M, Warden D, Wisniewski SR, Miyahara S, Rush AJ: Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med 2010;40:41-50.
8. Koszewska I, Rybakowski JK: Antidepressantinduced mood conversions in bipolar disorder: a retrospective study of tricyclic versus non-tricyclic antidepressant drugs. Neuropsychobiology 2009;59:12-16.
9. Licht RW, Gijsman H, Nolen WA, Angst J: Are antidepressants safe in the treatment of bipolar depression? A critical evaluation of their potential risk to induce switch into mania or cycle acceleration. Acta Psychiatr Scand 2008;118:337-346.
10. Clark L, Chamberlain SR, Sahakian BJ: Neurocognitive mechanisms in depression: implications for treatment. Annu Rev Neurosci 2009;32:57-74.
11. Barker EL, Blakely RD: Identification of a single amino acid, phenylalanine 586, that is responsible for high affinity interactions of tricyclic antidepressants with the human serotonin transporter. Mol Pharmacol 1996;50:957-965.
12. Zhou Z, Zhen J, Karpowich NK, Goetz RM, Law CJ, Reith ME, Wang DN: LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake. Science 2007;317:1390-1393.
13. Zhou Z, Zhen J, Karpowich NK, Law CJ, Reith ME, Wang DN: Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. Nature Struct Mol Biol 2009;16:652-657.
14. Tang SW, Helmeste D: Paroxetine. Expert Opin Pharmacother 2008;9:787-794.
15. Kennedy SH, Andersen HF, Thase ME: Escitalopram in the treatment of major depressive disorder: a metaanalysis. Curr Med Res Opin 2009;25:161-175.
16. Chen F, Larsen MB, Sánchez C, Wiborg O: The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol 2005;15:193-198.
17. Zhong H, Hansen KB, Boyle NJ, Han K, Muske G, Huang X, Egebjerg J, Sánchez C: An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: kinetic binding studies with the ALI/VFL-SI/TT mutant. Neurosci Lett 2009;462:207-212.
18. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C: Comparative efficacy and acceptability of 12 newgeneration antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-758.
19. Marks DM, Pae C-U, Patka AA: Triple reuptake inhibitors: the next generation of antidepressants. Curr Neuropharmacol 2008;6:338-343.
20. Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, McGuire H, Barbui C: Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev 2009;2:CD006117.
21. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R: Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003;28:1400-1411.
22. Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN: Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants. CNS Spectr 2009;14:197-206.
23. Owen RT: Agomelatine: a novel pharmacological approach to treating depression. Drugs Today (Barc) 2009;45:599-608.
24. Dubovsky SL, Warren C: Agomelatine, a melatonin agonist with antidepressant properties. Expert Opin Investig Drugs 2009;18:1533-1540.
25. Tang SW, Helmeste DM, Stancer HC: The effect of acute and chronic desipramine and amitriptyline treatment on rat brain total 3methoxy-4-hydroxyphenylglycol. Naunyn Schmiedebergs Arch Pharmacol 1978;305:207-211.
26. Tang SW, Seeman P, Kwan S: Differential effect of chronic desipramine and amitriptyline treatment on rat brain adrenergic and serotonergic receptors. Psychiatry Res 1981;4:129-138.
27. Tang SW, Seeman P: Effect of antidepressant drugs on serotonergic and adrenergic receptors. Naunyn Schmiedebergs Arch Pharmacol 1980;311:255-261.
28. Helmeste DM, Tang SW: Unusual acute effects of antidepressants and neuroleptics on S2-serotonergic receptors. Life Sci 1983;33:2527-2533.
29. Dumbrille-Ross A, Tang SW, Coscina DV: Lack of effect of raphe lesions on serotonin S2 receptor changes induced by amitriptyline and desmethylimipramine. Psychiatry Res 1982;7:145-151.
30. Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, Molski TF, Yocca FD, Sharp T, Kikuch T, Burris KD: Interaction of the novel antipsychotic aripiprazole with 5HT1A and 5HT2A receptors: functional receptor-binding and in vivo electrophysiological studies. Psychopharmacology (Berl) 2007;190:373-382.
31. Marek GJ, McDougle CJ, Price LH, Seiden LS: A comparison of trazodone and fluoxetine: implications for a serotonergic mechanism of antidepressant action. Psychopharmacology (Berl) 1992;109:2-11.
32. Millan MJ, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, Rivet J-M, Cussac D: The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine 2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J Pharmacol Exp Ther 2003;306:954-964.
33. Blier P, Bergeron R, de Montigny C: Selective activation of postsynaptic 5-HT1A receptors induces rapid antidepressant response. Neuropsychopharmacology 1997;16:333-338.
34. Millan MJ, Brocco M, Gobert A, Dekeyne A: Anxiolytic properties of agomelatine: an antidepressant with melatonergic and serotonergic properties:role of 5HT2C receptor blockade. Psychopharmacology 2005;177:1-12.
35. Paizanis E, Renoir T, Lelievre V: Behavioural and neoplastic effects of the new-generation antidepressant agomelatine compared to fluoxetine in glucocorticoid receptor-impaired mice. Int J Neuropsychopharmacol 2010;13:759-774.
36. Kasper S, Hamon M: Beyond the monoamine hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action. World J Biol Psychiatry 2009;10:117-126.
37. Svenningsson P, Chergui K, Rachleff I, Flajolet M, Zhang X, El Yacoubi M, Vaugeois JM, Nomikos GG, Greengard P: Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 2006;311:77-80.
38. Heurteaux C, Lucas G, Guy N, El Yacoubi M, Thümmler S, Peng XD, Noble F, Blondeau N, Widmann C, Borsotto M, Gobbi G, Vaugeois JM, Debonnel G, Lazdunski M: Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype. Nat Neurosci 2006;9:1134-1141.
39. Gordon JA, Hen R: TREKing toward new antidepressants. Nat Neurosci 2006;9:1081-1083.
40. Kennard LE, Chumbley JR, Ranatunga KM, Armstrong SJ, Veale EL, Mathie A: Inhibition of the human two-pore domain potassium channel, TREK-1, by fluoxetine and its metabolite norfluoxetine. Br J Pharmacol 2005;144:821-829.
41. Dewey SL, Smith GS, Logan J, Brodie JD, Yu DW, Ferrieri RA, King PT, MacGregor RR, Martin TP, Wolf AP: GABAergic inhibition of endogenous dopamine release measured in vivo with 11C-raclopride and positron emission tomography. J Neurosci 1992;12:3773-3780.
42. Preda A, MacLean RW, Mazure CM, Bowers MB Jr: Antidepressant-associated mania and psychosis resulting in psychiatric admissions. J Clin Psychiatry 2001;62:30-33.
43. George TP, Vessicchio JC, Sacco KA, Weinberger AH, Dudas MM, Allen TM, Creeden CL, Potenza MN, Feingold A, Jatlow PI: A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry 2008;63:1092-1096.
44. Rosenzweig-Lipson S, Sabb A, Stack G, Mitchell P, Lucki I, Malberg JE, Grauer S, Brennan J, Cryan JF, Sukoff Rizzo SJ, Dunlop J, Barrett JE, Marquis KL: Antidepressant-like effects of the novel, selective, 5-HT2C receptor agonist WAY-163909 in rodents. Psychopharmacology (Berl) 2007;192:159-170.
45. Martin JR, Bös M, Jenck F, Moreau J, Mutel V, Sleight AJ, Wichmann J, Andrews JS, Berendsen HH, Broekkamp CL, Ruigt GS, Köhler C, Delft AM:5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J Pharmacol Exp Ther 1998;286:913-924.
46. Dekeyne A, Mannoury la Cour C, Gobert A, Brocco M, Lejeune F, Serres F, Sharp T, Daszuta A, Soumier A, Papp M, Rivet JM, Flik G, Cremers TI, Muller O, Lavielle G, Millan MJ: S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models. Psychopharmacology (Berl) 2008;199:549-568.
47. Dremencov E, Newman ME, Kinor N, Blatman-Jan G, Schindler CJ, Overstreet DH, Yadid G: Hyperfunctionality of serotonin-2C receptor-mediated inhibition of accumbal dopamine release in an animal model of depression is reversed by antidepressant treatment. Neuropharmacology 2005;48:34-42.
48. Werneck AL, Rosso AL, Vincent MB: The use of an antagonist 5-HT2a/c for depression and motor function in Parkinson' disease. Arq Neuropsiquiatr 2009;67:407-412.
49. Froestl W, Gallagher M, Jenkins H, Madrid A, Melcher T, Teichman S, Mondadori CG, Pearlman R: SGS: the first GABA(B) receptor antagonist in clinical trials. Biochem Pharmacol 2004;68:1479-1487.
50. Nowak G, Partyka A, Pałucha A, Szewczyk B, Wierońska JM, Dybała M, Metz M, Librowski T, Froestl W, Papp M, Pilc A: Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents. Br J Pharmacol 2006;149:581-590.
51. Nakagawa Y, Ishima T, Ishibashi Y, Yoshii T, Takashima T: Involvement of GABA(B) receptor systems in action of antidepressants: baclofen but not bicuculline attenuates the effects of antidepressants on the forced swim test in rats. Brain Res 1996;709:215-220.
52. Furukawa TA, Streiner DL, Young LT: Is antidepressant-benzodiazepine combination therapy clinically more useful? A meta-analytic study. J Affect Disord 2001;65:173-177.
53. Sacchetti G, Bonini I, Waeterloos GC, Samanin R: Tianeptine raises dopamine and blocks stressinduced noradrenaline release in the rat frontal cortex. Eur J Pharmacol 1993;236:171-175.
54. Mennini T, Mocaer E, Garattini S: Tianeptine, a selective enhancer of serotonin uptake in rat brain. Naunyn Schmiedebergs Arch Pharmacol 1987;336:478-482.
55. McEwen BS, Chattarji S, Diamond DM, Jay TM, Reagan LP, Svenningsson P, Fuchs E: The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation. Mol Psychiatry 2010;15:237-249.
56. Rakofsky JJ, Holtzheimer PE, Nemeroff CB: Emerging targets for antidepressant therapies. Curr Opin Chem Biol 2009;13:291-302.
57. Popik P, Krawczyk M, Golembiowska K, Nowak G, Janowsky A, Skolnick P, Lippa A, Basile AS: Pharmacological profile of the 'triple' monoamine neurotransmitter uptake inhibitor, DOV 102,677. Cell Mol Neurobiol 2006;26:857-873.
58. Guiard BP, El Mansari M, Blier P: Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors. Curr Drug Targets 2009;10:1069-1084.
59. Zarate CA Jr, Payne JL, Singh J, Quiroz JA, Luckenbaugh DA, Denicoff KD, Charney DS, Manji HK: Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004;56:54-60.
60. Sporn J, Ghaemi SN, Sambur MR, Rankin MA, Recht J, Sachs GS, Rosenbaum JF, Fava M: Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann Clin Psychiatry 2000;12:137-140.
61. Lee T, Tang SW: Reduced presynaptic dopamine receptor density after chronic antidepressant treatment in rats. Psychiatry Res 1982;7:111-119.
62. Clark L, Chamberlain SR, Sahakian BJ: Neurocognitive mechanisms in depression: implications for treatment. Annu Rev Neurosci 2009;32:57-74.
63. Quitkin FM, Liebowitz MR, Stewart JW, McGrath PJ, Harrison W, Rabkin JG, Markowitz J, Davies SO: l-Deprenyl in atypical depressives. Arch Gen Psychiatry 1984;41:777-781.
64. Berry MD, Juorio AV, Paterson IA: Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders. Prog Neurobiol 1994;44:141-161.
65. Gimenez-Roldan S, Dobato JL, Mateo D: Treatment of depression in Parkinson's disease with moclobemide:a pilot open-label study. Parkinsonism Relat Disord 1997;3:219-225.
66. Koszewska I, Rybakowski JK: Antidepressantinduced mood conversions in bipolar disorder: a retrospective study of tricyclic versus non-tricyclic antidepressant drugs. Neuropsychobiology 2009;59:12-16.
67. Gartlehner G, Hansen RA, Kahwati L, et al: Drug Class Review on Second-Generation Antidepressants. Final Report. Portland, Oregon Evidence-Based Practice Center, Oregon Health and Science University, 2006.
68. Warden D, Rush AJ, Trivedi M, Ritz L, Stegman D, Wisniewski SR: Quality improvement methods as applied to a multicenter effectiveness trial-STAR*D. Contemp Clin Trials 2005;26:95-112.
69. Rush AJ, Trivedi M, Fava M: Depression. 4. STAR*D treatment trial for depression. Am J Psychiatry 2003;160:237.
70. Papakostas GI, Fava M, Thase ME: Treatment of SSRI-resistant depression: a meta-analysis comparing within-versus across-class switches. Biol Psychiatry 2008;63:699-704.
71. Lee T, Tang SW: Loxapine and clozapine decrease serotonin (S2) but do not elevate dopamine (D2) receptor numbers in the rat brain. Psychiatry Res 1984;12:277-285.
72. Balu DT, Hoshaw BA, Malberg JE, Rosenzweig-Lipson S, Schechter LE, Lucki I: Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. Brain Res 2008;1211:37-43.
73. Keilhoff G, Grecksch G, Bernstein H-G, Roskoden T, Becker A: Risperidone and haloperidol promote survival of stem cells in the rat hippocampus. Eur Arch Psychiatry Clin Neurosci 2010;260:151-162.
74. Shelton RC, Osuntokun O, Heinloth AN, Corya SA: Therapeutic options for treatment-resistant depression. CNS Drugs 2010;24:131-161.
75. Carvalho AF, Machado JR, Cavalcante JL: Augmentation strategies for treatment-resistant depression. Curr Opin Psychiatry 2009;22:7-12.
76. Malhi GS, Adams D, Berk M: Is lithium in a class of its own? A brief profile of its clinical use. Aust NZ J Psychiatry 2009;43:1096-1104.
77. Tang SW, Remington G, Persad E, Rosenblat R: Coadministration of a beta-adrenergic antagonist and a tricyclic antidepressant: a pilot study. Psychiatry Res 1990;33:101-106.
78. Ballesteros J, Callado LF: Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomized controlled trials. J Affect Disord 2004;79:137-147.
79. Skolnick P, Popik P, Trullas R: Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 2009:30:563-569.
80. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW: An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatmentrefractory major depressive disorder. J Clin Psychopharmacol 2008;28:631-637.
81. Stahi SM: Basic psychopharmacology of antidepressants. 1. Antidepressants have seven distinct mechanisms of action. J Clin Psychiatry 1998;59(Suppl 4):5-14.
82. Dumas RS: Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med 2004;5:11-25.
83. Dumas RS: Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness:stress and depression. Dialogues Clin Neurosci 2009;11:239-255.
84. Ren-Patterson RF, Cochran LW, Holmes A, Sherrill S, Huang SJ, Tolliver T, Lesch KP, Lu B, Murphy DL: Loss of brain-derived neurotrophic factor gene allele exacerbates brain monoamine deficiencies and increases stress abnormalities of serotonin transporter knockout mice. J Neurosci Res 2005;79:756-771.
85. Thakker-Varia S, Krol JJ, Nettleton J, Bilimoria PM, Bangasser DA, Shors TJ, Black IB, Alder J: The neuropeptide VGF produces antidepressant-like behavioral effects and enhances proliferation in the hippocampus. J Neurosci 2007;27:12156-12167.
86. Hunsberger JG, Newton SS, Bennett AH, Duman CH, Russell DS, Salton SR, Duman RS: Antidepressant actions of the exercise-regulated gene VGF. Nature Med 2007;13:1476-1482.
87. Thakker-Varia S, Alder J: Neuropeptides in depression:role of VGF. Behav Brain Res 2009;197:262-278.
88. Boldrini M, Underwood MD, Hen R, Rosoklija GB, Dwork AJ, Mann JJ, Arango V: Antidepressants increase neural progenitor cells in the human hippocampus. Neuropsychopharmacology 2009;34:2376-2389.
89. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R: Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301:805-809.
90. Balu DT, Hodes GE, Anderson BT, Lucki I: Enhanced sensitivity of the MRL/MpJ Mouse to the neuroplastic and behavioral effects of chronic antidepressant treatments. Neuropsychopharmacology 2009;34:1764-1773.
91. Adachi M, Barrot M, Autry AE, Theobald D, Monteggia LM: Selective loss of brain-derived neurotrophic factor in the dentate gyrus attenuates antidepressant efficacy. Biol Psychiatry 2008;63:642-649.
92. Holick KA, Lee DC, Hen R, Dulawa SC: Behavioral effects of chronic fluoxetine in BALB/cJ mice do not require adult hippocampal neurogenesis or the serotonin 1A receptor. Neuropsychopharmacology 2008;33:406-417.
93. Lau WM, Qiu G, Helmeste DM, Lee TMC, Tang SW, So KF: Corticosteroid decreases subventricular zone cell proliferation, which could be reversed by paroxetine. Restor Neurol Neurosci 2007;25:17-23.
94. Qiu G, Helmeste DM, Samaranayake AN, Lau WM, Lee TM, Tang SW, So KF: Modulation of the suppressive effect of corticosterone on adult rat hippocampal cell proliferation by paroxetine. Neurosci Bull 2007;23:131-136.
95. Deltheil T, Guiard BP, Cerdan J, David DJ, Tanaka KF, Repérant C, Guilloux JP, Coudoré F, Hen R, Gardier AM: Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice. Neuropharmacology 2008;55:1006-1014.